Universitair Ziekenhuis Brussel, 1090, Brussels, Belgium.
University Hospital of Martinique, 97200, Fort-de-France, Martinique, France.
Breast Cancer. 2021 Jul;28(4):956-968. doi: 10.1007/s12282-021-01234-z. Epub 2021 Mar 10.
To evaluate the overall survival prognostic value of preoperative F-fluorodeoxyglucose positron emission tomography (PET) in breast cancer, as compared with the lymph node ratio (LNR).
Data were abstracted at a median follow-up 14.7 years from a retrospective cohort of 104 patients who underwent PET imaging before curative surgery. PET-Axillary|Sternal was classified as PET-positive if hypermetabolism was visualized in ipsilateral nodal axillary and/or sternal region, else as PET-negative. The differences of 15 years restricted mean survival time ∆ according to PET and LNR were computed from Kaplan-Meier overall survival. The effect of PET and other patients' characteristics was analyzed through rankit normalization, which provides with Cox regression the Royston-Sauerbrei D measure of separation to compare the characteristics (0 indicating no prognostic value). Multivariate analysis of the normalized characteristics used stepwise selection with the Akaike information criterion.
In Kaplan-Meier analysis, LNR > 0.20 versus ≤ 0.20 showed ∆ = 3.4 years, P = 0.003. PET-Axillary|Sternal positivity versus PET-negative showed a ∆ = 2.6 years, P = 0.008. In Cox univariate analyses, LNR appeared as topmost prognostic separator, D = 1.50, P < 0.001. PET ranked below but was also highly significant, D = 1.02, P = 0.009. In multivariate analyses, LNR and PET-Axillary|Sternal were colinear and mutually exclusive. PET-Axillary|Sternal improved as prognosticator in a model excluding lymph nodes, yielding a normalized hazard ratio of 2.44, P = 0.062.
Pathological lymph node assessment remains the gold standard of prognosis. However, PET appears as a valuable surrogate in univariate analysis at 15-year follow-up. There was a trend towards significance in multivariate analysis that warrants further investigation.
与淋巴结比值(LNR)相比,评估术前 F-氟代脱氧葡萄糖正电子发射断层扫描(PET)在乳腺癌患者中的总体生存预后价值。
从接受 PET 成像检查后进行根治性手术的 104 例患者的回顾性队列中,中位随访 14.7 年后提取数据。如果同侧淋巴结腋部和/或胸骨区域可见代谢亢进,则将 PET-Axillary|Sternal 分类为 PET 阳性,否则为 PET 阴性。通过 Kaplan-Meier 总体生存计算了根据 PET 和 LNR 的 15 年限制平均生存时间 ∆ 的差异。通过秩和检验标准化分析 PET 和其他患者特征的差异,该方法通过 Cox 回归为 Royston-Sauerbrei D 分离度量提供了比较特征的方法(0 表示没有预后价值)。使用逐步选择和 Akaike 信息准则对标准化特征进行多变量分析。
在 Kaplan-Meier 分析中,LNR>0.20 与≤0.20 相比, ∆=3.4 年,P=0.003。PET-Axillary|Sternal 阳性与 PET 阴性相比, ∆=2.6 年,P=0.008。在 Cox 单变量分析中,LNR 是最显著的预后分离因素,D=1.50,P<0.001。PET 排在后面,但也具有高度显著性,D=1.02,P=0.009。在多变量分析中,LNR 和 PET-Axillary|Sternal 是共线性的,且相互排斥。在排除淋巴结的模型中,PET-Axillary|Sternal 作为预后指标得到改善,标准化风险比为 2.44,P=0.062。
病理性淋巴结评估仍然是预后的金标准。然而,在 15 年的随访中,PET 在单变量分析中表现出有价值的替代物。多变量分析中存在进一步研究的趋势,表明其具有一定的显著性。